Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer
Corticosteroids have been used in the therapy for castration-resistant prostate cancer (CRPC) for decades, both as monotherapy and in combination with additional agents. In this article the authors report the results of a phase II trial of dexamethasone versus prednisolone as monotherapy for CRPC. T...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Taylor & Francis
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622618/ |